Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 2
2003 3
2004 7
2005 7
2006 8
2007 9
2008 15
2009 25
2010 16
2011 22
2012 28
2013 47
2014 57
2015 47
2016 51
2017 61
2018 75
2019 75
2020 95
2021 124
2022 139
2023 116
2024 66

Text availability

Article attribute

Article type

Publication date

Search Results

982 results

Results by year

Filters applied: . Clear all
Page 1
Incidence, mortality, survival, risk factor and screening of colorectal cancer: A comparison among China, Europe, and northern America.
Li N, Lu B, Luo C, Cai J, Lu M, Zhang Y, Chen H, Dai M. Li N, et al. Among authors: lu m. Cancer Lett. 2021 Dec 1;522:255-268. doi: 10.1016/j.canlet.2021.09.034. Epub 2021 Sep 24. Cancer Lett. 2021. PMID: 34563640 Review.
Colorectal cancer (CRC) is one of the most common malignancies worldwide. China, Europe and northern America account for more than half of the new CRC cases and associated deaths globally. This review summarizes the current status and temporal trends of CRC in China …
Colorectal cancer (CRC) is one of the most common malignancies worldwide. China, Europe and northern America account for more than ha …
Claudin18.2-specific CAR T cells in gastrointestinal cancers: phase 1 trial interim results.
Qi C, Gong J, Li J, Liu D, Qin Y, Ge S, Zhang M, Peng Z, Zhou J, Cao Y, Zhang X, Lu Z, Lu M, Yuan J, Wang Z, Wang Y, Peng X, Gao H, Liu Z, Wang H, Yuan D, Xiao J, Ma H, Wang W, Li Z, Shen L. Qi C, et al. Among authors: lu m. Nat Med. 2022 Jun;28(6):1189-1198. doi: 10.1038/s41591-022-01800-8. Epub 2022 May 9. Nat Med. 2022. PMID: 35534566 Free PMC article. Clinical Trial.
Ciprofol: A Novel Alternative to Propofol in Clinical Intravenous Anesthesia?
Lu M, Liu J, Wu X, Zhang Z. Lu M, et al. Biomed Res Int. 2023 Jan 19;2023:7443226. doi: 10.1155/2023/7443226. eCollection 2023. Biomed Res Int. 2023. PMID: 36714027 Free PMC article. Review.
Ciprofol is a novel compound that was independently developed in China. According to the Chinese product instructions approved by the China National Medical Products Administration and the information of official website, indications for ciprofol include sedation an …
Ciprofol is a novel compound that was independently developed in China. According to the Chinese product instructions approved by the …
Non-invasive early detection of cancer four years before conventional diagnosis using a blood test.
Chen X, Gole J, Gore A, He Q, Lu M, Min J, Yuan Z, Yang X, Jiang Y, Zhang T, Suo C, Li X, Cheng L, Zhang Z, Niu H, Li Z, Xie Z, Shi H, Zhang X, Fan M, Wang X, Yang Y, Dang J, McConnell C, Zhang J, Wang J, Yu S, Ye W, Gao Y, Zhang K, Liu R, Jin L. Chen X, et al. Among authors: lu m. Nat Commun. 2020 Jul 21;11(1):3475. doi: 10.1038/s41467-020-17316-z. Nat Commun. 2020. PMID: 32694610 Free PMC article.
Changing trends in the disease burden of esophageal cancer in China from 1990 to 2017 and its predicted level in 25 years.
Li S, Chen H, Man J, Zhang T, Yin X, He Q, Yang X, Lu M. Li S, et al. Among authors: lu m. Cancer Med. 2021 Mar;10(5):1889-1899. doi: 10.1002/cam4.3775. Epub 2021 Feb 14. Cancer Med. 2021. PMID: 33586344 Free PMC article.
BACKGROUND: Nearly half of the cases of esophageal cancer in the world were in China, but the corresponding burden in China has not been estimated for the past decades or for the near future. METHODS: Data on the incidence, mortality, and disability-adjusted life ye …
BACKGROUND: Nearly half of the cases of esophageal cancer in the world were in China, but the corresponding burden in China ha …
Olverembatinib (HQP1351), a well-tolerated and effective tyrosine kinase inhibitor for patients with T315I-mutated chronic myeloid leukemia: results of an open-label, multicenter phase 1/2 trial.
Jiang Q, Li Z, Qin Y, Li W, Xu N, Liu B, Zhang Y, Meng L, Zhu H, Du X, Chen S, Liang Y, Hu Y, Liu X, Song Y, Men L, Chen Z, Niu Q, Wang H, Lu M, Yang D, Zhai Y, Huang X. Jiang Q, et al. Among authors: lu m. J Hematol Oncol. 2022 Aug 18;15(1):113. doi: 10.1186/s13045-022-01334-z. J Hematol Oncol. 2022. PMID: 35982483 Free PMC article. Clinical Trial.
982 results